Thai PBS Thai PBS
Lilly drug slows Alzheimer's progression by 35% in trial

Lilly drug slows Alzheimer's progression by 35% in trial

14 Sept 01:43 Key points summarised by AI
  • Eli Lilly's experimental drug, donanemab, significantly slowed cognitive decline by 35% in patients with early-stage Alzheimer's in a closely watched late-stage trial.
  • The results are considered the 'strongest phase 3 data' for an Alzheimer's treatment to date, raising hopes for a second effective therapy that surpasses previous options like Leqembi.
  • Notable side effects included brain swelling (24% incidence) and brain bleeding (31.4% incidence), with some serious cases and deaths reported.
  • Lilly plans to file for traditional U.S. approval for donanemab by the end of June, aiming to make this new treatment available.
Read full article
World 1/2
Skip > Skip >